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Parathyroidectomy: Whom and when? Hyperparathyroidism stages, this treatment is effective, but as secondary hyper-
(HPT) is common in patients on dialysis, and parathyroidec- parathyroidism progresses, the gland becomes resistant
tomy (PTx) is often required. We present a retrospective, de- and the patient starts to present with hypercalcemiascriptive analysis of data corresponding to 148 patients on
and/or hyperphosphatemia [2]. The association betweendialysis undergoing PTx due to severe refractory HPT (PTH
high calcium and phosphate levels and higher morbidity1401  497 pg/mL, Ca 10.6  0.8 mg/dL, P 6.9  1.7 mg/dL).
Demographic data were compared with those recorded in 309 and mortality, especially cardiovascular, has been dem-
patients on dialysis not subjected to PTx who were managed onstrated in patients with chronic renal insufficiency, and
at the same hospital. In the PTx group, the factors age (49.3  presents with values of the calcium x phosphate product14 years), male gender (48.6%), and diabetes (0.7%) were
55 mg2/dL2, which were considered safe [3] until re-significantly lower than in the non-PTx group (61.5  14.9
cently.years, male gender 59%, diabetes 19.4%), while time on dialysis
was longer (8.6  5.8 vs. 5.5  5.4 years). In 129 of the study Further therapeutic options, such as vitamin D metab-
patients (87.4%), four or more glands were identified, and olites, calcimimetics, or aluminium- and calcium-free
total PTx plus autotransplantation (AT) in the forearm was
phosphate-binding agents have not been able to satisfac-performed. In the remaining 19 patients, two to three glands
torily resolve the problem or are still at an early stagewere identified, and AT was not undertaken. Four of the 19
patients were successfully operated on again for persistent of development [4–7].
HPT, seven showed PTH levels 250 pg/mL, and eight main- Parathyroidectomy (PTx) is the treatment of choice
tained severe HPT. Perioperative complications included one in patients with severe HPT and is the safest option when
death due to cardiac insufficiency, two repeat operations due
medical approaches have failed [8]. Correct evaluationto bleeding, and one patient with chronic hoarseness. Hospital
of a lack of response to treatment is essential to avoidstay was prolonged in 20% of patients due to a hungry bone
syndrome. Among those patients with PTx and AT, HPT re- unnecessary risk to the patient. The surgical techniques
curred in 21 patients (16.2%) at 3.1  2.3 years. In 13 of these employed and subsequent management are crucial fac-
patients, autograft was removed at 7.5  2.9 years. Serum cal- tors for outcome. The last few years have also seen alter-cium and phosphate levels improved after PTx, and these re-
native strategies to surgical PTx, including percutaneoussults were maintained for 5 years (9.6  0.8 and 4.2  1.2
intraglandular ethanol or calcitriol injection [9].mg/dL, respectively). In conclusion, PTx with AT is a safe
option for the treatment of severe HPT that is accompanied The aim of this study was to evaluate, in terms of
by low morbidity and mortality and a good outcome. Medical surgical indications and their early and late results, data
treatment should not be prolonged at the expense of long corresponding to a series of patients from our centerrepeated bouts of hypercalcemia and/or hyperphosphatemia
with severe HPT who were subjected to total PTx withwith their irreversible consequences.
autotransplantation (AT).
Over the past twenty years, secondary hyperparathy- METHODS
roidism has been mainly managed by combination treat-
The study population selected was treated at our dial-ment with calcium salts and calcitriol [1]. This approach
ysis unit and two of its satellite hemodialysis centers,leads to a positive calcium balance and enhanced intesti-
where there are presently 329 patients on hemodialysisnal absorption of calcium and phosphate. In its initial
(HD), and 30 on peritoneal dialysis (PD). We retrospec-
tively examined data derived from 148 patients (145 on
HD, 3 on DP) who had been parathyroidectomized dueKey words: parathyroidectomy, hyperparathyroidism recurrence, hy-
perparathyroidism persistence. to severe HPT over the period of January 1990 to March
2002. The demographic characteristics of the study pa- 2003 by the International Society of Nephrology
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Table 1. Demographic data
Patients with PTx Control
N  148 N  309
Age years 4914 61.514.9a
Gender % male 48.6% 59%b
Time on dialysis years 8.65.8 5.55.4a
Diabetic 0.7% 19.4%a
Nondiabetic 99.3% 80.6%
Data were performed using Student t test.
a P  0.001
b P  0.05
tients were compared to those of patients undergoing
dialysis at the same centers but who did not undergo
surgical treatment (Table 1). All the patients had been
treated with oral or intravenous calcitriol, calcium salts, Fig. 1. Evolution of parathyroid function after PTx in the 129 patients
(top) in whom 4 or more glands were identified (PTx and AT), and inand aluminum hydroxide. PTH levels were determined
the 19 patients (bottom) with only 3/2 glands identified at surgery (PTxby RIA DPC Immulite 2000 (Diagnostic Products Cor- without AT).
poration, Los Angeles, CA, USA) (normal range, 12 to
60 pg/mL).
Surgery was indicated in patients with persistently high
PTH levels (700 pg/mL) and hypercalcemia and/or hy- was subsequently identified by 99mTc-MIBI scintigraphy
perphosphatemia, as well as in cases of transient PTH in another six patients, four of whom were operated on
decrease associated with hypercalcemia and/or hyper- again successfully. Eight patients showing PTH 700
phosphatemia, which required the repeated withdrawal pg/mL were not operated on again for medical reasons
of treatment. In four patients with spontaneous breakage or at the patient’s request (Fig. 1).
of the quadriceps tendon, immediate surgery was indi- The number of complications related to surgery was
cated. low: one death due to heart failure, two repeated inter-
The surgical technique of choice was total PTx plus ventions due to bleeding, and one patient with chronic
forearm AT, whereby fragments of the least nodular hoarseness. Twenty percent of the patients presented
gland, as determined by microscopy, were selected for with hungry bone syndrome (Ca 8.0 mg/dL for over 8
AT. Surgery was exhaustive, with excision of the fatty days, despite high doses of oral or intravenous calcium
tissue surrounding the glands, resection of the thymus and treatment with calcitriol). These patients were sig-
remains, and bilateral opening of carotid sheaths. nificantly younger than the remaining patients, and pre-
surgery PTH and alkaline phosphatase values were sig-Statistical analysis
nificantly higher (data not shown).
Comparison of non-paired data between the two Seventy-nine point five percent of glands showed nod-
groups was performed by the Student t test. Qualitative ular hyperplasia, which was multinodular in 83.5%.
variables were compared by the chi-square test. Analysis Mean glandular weight was 1.18  1.55 g. In the re-
of variance (ANOVA) was used to compare paired data. maining 20.5%, hyperplasia was diffuse, with the mean
The level of significance was set at P  0.05.
weight of the glands being 0.628  0.784 g. Glandular
asymmetry was observed in 77% of the patient series.
RESULTS Mean length of follow-up was 5.2  3.9 years. At the
time of writing, 56 patients (37.8%) were still on dialysis,Patients selected for PTx were significantly younger
30 (20.2%) had received a transplant, 41 patients hadand had been on dialysis for a longer duration. There
died (28.7%) 3.5  2.9 years after surgery, and the re-was an increased proportion of women and lower inci-
maining 21 patients (13.8%) had been lost to follow-up.dence of diabetes in the PTx group than in the non-PTx
Table 2 shows the patients’ analytical profiles, whichgroup (Table 1).
indicate good serum calcium and phosphate control withIn 129 patients (87.7%), four or more glands were
normalization of the calcium x phosphate product fiveidentified; these patients were subjected to total PTx plus
years after surgery. All the patients are still under treat-AT. In the remaining 19 patients (12.3%), only 3 (17
ment with calcium salts and/or calcitriol.patients) or 2 glands (two patients) were identified, and
Recurrence of HPT (PTH 250 pg/mL) occurred inAT was not performed. Seven of these patients showed
PTH levels 250 pg /mL. An ectopic mediastinal gland 21 patients (16%) at 3.1  2.3 years. In 13 patients,
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Table 2. Analytical changes post-PTx
Basal N  148 1 year N  89 2 years N  75 5 years N  69
PTH pg/mL 1401497a 154246 100132 249480
Ca mg/dL 10.60.8a 9.50.9 9.60.8 9.60.8
P mg/dL 6.91.7a 5.21.2 5.01.8 4.21.2
Ca x P mg2/dL2 61.523.1a 46.519.5 46.315.4 42.314.1
AP Ul 737519a 253130 21588 232159
The difference was found to be significant by analysis of variance (ANOVA).
a P  0.001
the AT was removed under local anesthesia. Nodular [17]. Four of our patients suffered spontaneous breakage
of the quadriceps tendon. When associated with severehyperplasia was observed in all cases.
HPT, calciphylaxia is an urgent indication for surgeryAt 7.5  2.9 years, 21 patients persistently showed
[17]. Surgery leads to improved bone pain, muscle weak-PTH levels 30 pg/mL with no apparent clinical conse-
ness, and pruritus. Soft tissue, but not vessel, calcificationquences.
subsides [17, 18].
Risk factors associated with HPT include: black race,
DISCUSSION younger age, female gender, longer time on dialysis, and
In our series, PTx with AT proved effective and safe hemodialysis versus peritoneal dialysis [19–22]. In our
in patients in whom medical treatment had failed, partic- series, patients requiring PTx were significantly younger,
ularly in terms of improving calcium and phosphate con- and the percentage of women and time on dialysis were
trol. There is growing evidence of the importance of the greater than the mean corresponding to all patients man-
early identification of patients in whom treatment is not aged at our center. The incidence of diabetes was low,
only ineffective, but which also leads to devastating con- as described in another series [23].
sequences, including increasing morbidity and mortality There is still much dispute over the most efficient
especially at the cardiovascular level [3]. PTH has a series surgical technique in terms of avoiding both recurrence
of direct effects on cardiac function, hypertrophy, myo- and the development of adynamic bone disease. Three
cardial fibrosis, ischemia, and atherosclerosis [10]. Re- procedures are employed in current clinical practice: to-
cent studies have demonstrated a relationship between tal PTx, total PTx with AT, and subtotal PTx (whereby
myocardial, valve, coronary, and vascular calcifications a fragment of the gland is left in situ) [8]. Our procedure
with an enhanced Ca x P product and raised intake of of choice was total PTx with AT in the forearm. The
calcium salts [3, 10–14]. recurrence rate was 16%. Tominaga et al [18] reported
Indicators of medical treatment failure are mostly bio- recurrence rates of 10%, 20%, and 30% at 1, 5, and 7
chemical. A lack of response is defined as persistently years, respectively, in a series of 1053 patients treated
high serum PTH levels (8 to 10 times above normal with an operative procedure similar to ours. In a review
values) in the presence of hypercalcemia and/or hyper- of 1299 cases published until 1990 (920 total PTX plus
phosphatemia, or when there is transient PTH decrease AT, 379 subtotal PTX), Rothmund observed no differ-
accompanied by repeated episodes of hypercalcemia ence in the outcome of either technique. Similar findings
and/or hyperphosphatemia, requiring the repeated inter- have been reported by others [24, 25, 26].
ruption of treatment. In this situation, treatment should In patients with an AT, recurrence depends in part
not be continued for longer than 6 to 8 months to avoid on maintaining the uremic environment and the charac-
irreversible complications [8, 15]. teristics of the transplanted tissue. Microscopy appear-
Isolated high PTH values are not, in themselves, an ance is of limited use when selecting the tissue for im-
indication for surgery but may predict the outcome of plant, although some investigators have obtained good
medical treatment. Rodrı´guez et al [16] examined 50 results using a stereomagnifier system [27]. It has been
patients on HD treated with calcitriol and defined a proposed that the autograft should be taken from the
response to treatment as a 40% decrease in basal PTH smallest gland [18], and this is our current policy. Glands
levels at 2 months. In patients with PTH values above showing a volume larger than or 500 mm3, or any diame-
750 and 1200 pg/mL, the likelihood of an adequate re- ter greater than 1 cm on ultrasonography, are associated
sponse is 50% and 20%, respectively. with 80% nodular transformation, rendering them treat-
Clinical findings are important for establishing when ment resistant [18]. Glandular size is currently accepted
surgery is indicated, though correlation with PTH values as an indication for surgery.
is highly variable. Bone pain, myopathy, metastatic calci- When HPT recurs, the PTH gradient between each
arm helps to identify whether the excess PTH is associ-fication, and pruritus are the most common symptoms
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dialysis patients—the Japanese strategy. Nephrol Dial Transplantated with the graft or with ectopic parathyroid tissue
14:2574–2577, 1999
[28]. Treating a recurrence is easier when the patient 10. Rostand SG, Drue¨ke TB: Parathyroid hormone, vitamin D, and
cardiovascular disease in chronic renal failure. Kidney Int 56:383–has undergone AT rather than subtotal PTx. In our se-
392, 1999ries, the forearm autograft was removed under local an-
11. Goodman WG, Goldin J, Kuizon BD, et al: Coronary-artery calci-
esthesia in an outpatient setting. In some cases, surgery fication in young adults with end-stage renal disease who are under-
going dialysis. N Engl J Med 342:1478–1483, 2000was laborious due to infiltration of parathyroid tissue in
12. Raggi P: Detection and quantification of cardiovascular calcifica-the muscle. All the grafts removed presented with nodu-
tions with electron beam tomography to estimate risk in hemodialy-
lar transformation. sis patients. Clin Nephrol 54:325–333, 2000
13. Guerin AP, London GM, Marchais SJ, Metivier F: ArterialIn patients not on the transplant waiting list who show
stiffening and vascular calcification in end stage renal disease.little adherence to treatment, some authors advocate
Nephrol Dial Transplant 15:1014–1021, 2000
total PTx plus cryopreservation of glandular tissue for 14. Kimura K, Saika Y, Otani H, et al: Factors associated with calcifi-
cation of the abdominal aorta in hemodialysis patients. Kidney Intsubsequent autografting, if necessary [29, 30]. The com-
(Suppl 71):S238–241, 1999mon existence of ectopic parathyroid tissue and scarce
15. Schomig M, Ritz E: Management of disturbed calcium metabolism
clinical relevance of hypoparathyroidism in patients on in uremic patients. 2. Indications for parathyroidectomy. Nephrol
Dial Transplant 15 (Suppl 5):S25–S29, 2000dialysis lends support to this practice, although only a
16. Rodrı´guez M, Caravaca F, Fernandez E, et al: Parathyroid func-few patients have been monitored thus far. In 21 of our
tion as a determinant of the response to calcitriol treatment in the
patients, PTH levels as low as 30 pg/mL persisted for hemodialysis patient. Kidney Int 56:306–317, 1999
17. Llach F, Velasquez Forero F: Secondary hyperparathyroidism5 to 10 years with no apparent clinical consequences.
in chronic renal failure: Pathogenic and clinical aspects. Am JIn conclusion, in patients with severe HPT, total PTx
Kidney Dis 38(Suppl 5):S20–S33, 2001
with AT appears to be safe and effective when nonsurgi- 18. Tominaga Y, Uchida K, Haba T, et al: More than 1,000 cases of
total parathyroidectomy with forearm autograft for renal hyper-cal treatment fails. In the hands of an experienced sur-
parathyroidism. Am J Kidney Dis 38(Suppl 1):S168–171, 2001geon, operative morbidity is low. The procedure should
19. Gupta A, Kallenbag LR, Zasuwa G, Divine GW: Race is a
be performed as early as possible to avoid the adverse, major determinant of secondary hyperparathyrodisim in uremia.
Am J Soc Nephrol 11:330–334, 2000irreversible effects of prolonged hypercalcemia/hyper-
20. Chertow GM, Plone M, Dillon MA, et al: Hyperparathyroidismphosphatemia, and to improve osteoarticular symptoms.
and dialysis vintage. Clin Nephrol 54:295–300, 2000
Subsequent management should be cautious, avoiding 21. Malberti F, Marcelli D, Conte F, et al: Parathyroidectomy in
patients on renal replacement therapy: An epidemiologic study.both relapse and exposure to inadequate levels of serum
J Am Soc Nephrol 12:1242–1248, 2001calcium and phosphate in patients with possible low bone
22. Torres A, Lorenzo V, Hernandez D, et al: Bone disease in
turnover. predialysis, hemodialysis and CAPD patients: Evidence to a better
response to PTH. Kidney Int 47:1434–1442, 1995
23. Inaba M, Okuno S, Nagasue K, et al: Impaired secreation ofREFERENCES
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